Following subcutaneous administration in clinical models: Both components demonstrate prolonged absorption with peak plasma concentrations occurring 24-72 hours post-injection GLP3 exhibits approximately 6-day half-life enabling once-weekly dosing Cagrilintide demonstrates 120-165 hour half-life (5-7 days) suitable for weekly administration Lipid conjugation of both peptides enables albumin binding and extended systemic circulation Distribution patterns show systemic exposure with concentration in metabolically active tissues The fatty diacid modifications on both peptides (C20 for GLP3 , eicosanedioic acid for cagrilintide) serve as albumin-binding moieties that dramatically extend plasma residence time compared to native peptides
BPC-157s systemic distribution, even from abdominal injection sites, offers a practical delivery mechanism for reaching thoracic injuries
Frequently Asked Questions About BPC-157 What is BPC-157 and how does it work
Activation by oxidatively modified ldl and 4-hydroxynonenal
Arora S , Senapati J, Short N, Yilmaz M, Loghavi S, Kadia T, DiNardo C, Borthakur G, Jabbour J, Goulart H, Issa G, Pemmaraju N, Jen W, Abbas H, Andreeff M , Kantarjian H, GarciaManero G, Ravandi F, Naval D